Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Cynthia, X.; J. Suman, Vera; Marilyn Leitch, A.; Sanati, Souzan; Vij, Kiran; Unzeitig, Gary; Hoog, Jeremy; A. Watson, Mark; Hahn, Olwen; M. Guenther, Joseph; S. Caudle, Abigail; C. Crouch, Erika; Maluf, Horacio; Tiersten, Amy; Mita, Monica; Razaq, Wajeeha; J. Hieken, Tina; Wang, Yang; Dockter, Travis; Anne Zujewski, Jo; Weiss, Anna; K. Hunt, Kelly; A. Hudis, Clifford; P. Winer, Eric; J. Ellis, Matthew; A. Carey, Lisa; H. Partridge, Ann

doi:10.1158/1538-7445.sabcs20-gs4-05

Public

Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Shared by NobleBlocks on Feb 15, 2021 • 12:00 AM UTC

Authors:

X. Cynthia

Vera J. Suman

A. Marilyn Leitch

Abstract

Abstract Background: Ki67 values &gt;10% 2-4 weeks (wks) after starting neoadjuvant ET (NET) indicates persistent cell proliferation, resistance to ET, and is associated with increased risk of recurrence. The ACOSOG Z1031 trial suggested that these tumors are also relatively chemotherapy (chemo)...

Subject

Medicine

Breast cancer

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!